Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin.

Kenawy S, Hegazy R, Hassan A, El-Shenawy S, Gomaa N, Zaki H, Attia A.

PLoS One. 2017 Aug 23;12(8):e0183565. doi: 10.1371/journal.pone.0183565. eCollection 2017.

2.

Recovery of hippocampal functions and modulation of muscarinic response by electroacupuncture in young diabetic rats.

Soligo M, Piccinin S, Protto V, Gelfo F, De Stefano ME, Florenzano F, Berretta E, Petrosini L, Nisticò R, Manni L.

Sci Rep. 2017 Aug 22;7(1):9077. doi: 10.1038/s41598-017-08556-z.

3.

Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.

Tong M, Leão R, Vimbela GV, Yalcin EB, Kay J, Krotow A, de la Monte SM.

Mol Cell Neurosci. 2017 Jul;82:23-34. doi: 10.1016/j.mcn.2017.04.010. Epub 2017 Apr 21.

PMID:
28438696
4.

Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology.

Gratuze M, Julien J, Petry FR, Morin F, Planel E.

Sci Rep. 2017 Apr 12;7:46359. doi: 10.1038/srep46359.

5.

Neural stem cell therapy for neurodegenerative disorders: The role of neurotrophic support.

Marsh SE, Blurton-Jones M.

Neurochem Int. 2017 Jun;106:94-100. doi: 10.1016/j.neuint.2017.02.006. Epub 2017 Feb 20. Review.

PMID:
28219641
6.

Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease.

de la Monte SM.

Drugs. 2017 Jan;77(1):47-65. doi: 10.1007/s40265-016-0674-0. Review.

PMID:
27988872
7.

The therapeutic potential of metabolic hormones in the treatment of age-related cognitive decline and Alzheimer's disease.

Grizzanti J, Lee HG, Camins A, Pallas M, Casadesus G.

Nutr Res. 2016 Dec;36(12):1305-1315. doi: 10.1016/j.nutres.2016.11.002. Epub 2016 Nov 8. Review.

8.
9.

Diabetes mellitus and cognitive impairments.

Saedi E, Gheini MR, Faiz F, Arami MA.

World J Diabetes. 2016 Sep 15;7(17):412-22. doi: 10.4239/wjd.v7.i17.412. Review.

10.

Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal.

Kandimalla R, Thirumala V, Reddy PH.

Biochim Biophys Acta. 2017 May;1863(5):1078-1089. doi: 10.1016/j.bbadis.2016.08.018. Epub 2016 Aug 25. Review.

PMID:
27567931
11.

Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies.

Tong M, Dominguez C, Didsbury J, de la Monte SM.

J Alzheimers Dis Parkinsonism. 2016 Jun;6(3). pii: 238. Epub 2016 Jun 3.

12.

Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease.

Salameh TS, Rhea EM, Banks WA, Hanson AJ.

Exp Biol Med (Maywood). 2016 Sep;241(15):1676-83. doi: 10.1177/1535370216660770. Epub 2016 Jul 28. Review.

13.

Changes in insulin and insulin signaling in Alzheimer's disease: cause or consequence?

Stanley M, Macauley SL, Holtzman DM.

J Exp Med. 2016 Jul 25;213(8):1375-85. doi: 10.1084/jem.20160493. Epub 2016 Jul 18. Review.

14.

Complex mechanisms linking neurocognitive dysfunction to insulin resistance and other metabolic dysfunction.

Stoeckel LE, Arvanitakis Z, Gandy S, Small D, Kahn CR, Pascual-Leone A, Pawlyk A, Sherwin R, Smith P.

Version 2. F1000Res. 2016 Mar 15 [revised 2016 Jan 1];5:353. doi: 10.12688/f1000research.8300.2. eCollection 2016. Review.

15.

Meta-Analysis of Serum Insulin-Like Growth Factor 1 in Alzheimer's Disease.

Ostrowski PP, Barszczyk A, Forstenpointner J, Zheng W, Feng ZP.

PLoS One. 2016 May 26;11(5):e0155733. doi: 10.1371/journal.pone.0155733. eCollection 2016.

16.

The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice.

Puig KL, Kulas JA, Franklin W, Rakoczy SG, Taglialatela G, Brown-Borg HM, Combs CK.

Neurobiol Aging. 2016 Apr;40:22-40. doi: 10.1016/j.neurobiolaging.2015.12.021. Epub 2016 Jan 6.

17.

Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1.

Schilling MA.

J Alzheimers Dis. 2016;51(4):961-77. doi: 10.3233/JAD-150980. Review.

19.

T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease.

Tong M, Deochand C, Didsbury J, de la Monte SM.

J Alzheimers Dis. 2016;51(1):123-38. doi: 10.3233/JAD-151013.

20.

Cigarette Smoke-Induced Alterations in Frontal White Matter Lipid Profiles Demonstrated by MALDI-Imaging Mass Spectrometry: Relevance to Alzheimer's Disease.

Nunez K, Kay J, Krotow A, Tong M, Agarwal AR, Cadenas E, de la Monte SM.

J Alzheimers Dis. 2016;51(1):151-63. doi: 10.3233/JAD-150916.

Supplemental Content

Support Center